We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ANSM: ‘Off-Target Effect’ of Compound Likely Cause of Trial Disaster
ANSM: ‘Off-Target Effect’ of Compound Likely Cause of Trial Disaster
After a Phase 1 trial designed by Portuguese drugmaker Bial Laboratories left one patient dead and the hospitalization of others, a committee appointed by France’s Agency for Medicines and Health Products Safety determined that an “off-target effect” of the compound is a probable explanation for the tragedy.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor